# A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

> **NCT05877820** · PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Fumarate Hydratase Deficient Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Tislelizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05877820
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877820, "A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05877820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*